ITRM logo

Iterum Therapeutics plc Ordinary Share


ITRM: Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.


Show ITRM Financials

Consumer Interest
SEC Filings

Recent trades of ITRM by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by ITRM's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Combinations of beta-lactam compounds and probenecid and uses thereof Oct. 25, 2022
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of ITRM in WallStreetBets Daily Discussion


Recent insights relating to ITRM

CNBC Recommendations

Recent picks made for ITRM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ITRM

Corporate Flights

Flights by private jets registered to ITRM